Checkpoint Inhibitor Pneumonitis Mimicking COVID-19 infection during the COVID-19 pandemic
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Dear Editors, As of May 27, 2020, 5,612,601 people have been diagnosed with COVID-19 and 349,060 deaths have been recorded, with a mortality rate of up to 6.22 % worldwide. Despite the current COVID-19 pandemic, many advanced lung cancer patients continue to receive regular immunotherapy, such as programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand (PDL-1) checkpoint inhibitors (CIs) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), as salvage therapies. Checkpoint inhibitor pneumonitis (CIP) is the most common fatal immune-related adverse event (irAE) in lung cancer patients receiving Cls and CIP related mortality may more than 20 %. During current COVID-19 pandemic, CIP is hard to distinguish from COVID-19 infection as they share similar clinical and radiographic presentations but different therapy strategies. Therefore, how to distinguish between the two diseases is an urgent issue.
Lung Cancer , article en libre accès, 2019